|
| 38042525 | CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2024 |
| 36270866 | Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. | Clin Lung Cancer | 2023 |
| 37633678 | Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies. | Lancet Public Health | 2023 |
| 37490292 | Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial. | JAMA Netw Open | 2023 |
| 37744308 | Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies. | JTO Clin Res Rep | 2023 |
| 37651139 | SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without Cancer. | JAMA Netw Open | 2023 |
| 37979334 | Presentation and outcomes of KRAS<sup>G12C</sup> mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. | Cancer Treat Res Commun | 2023 |
| 37931632 | Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. | Lancet | 2023 |
| 37379430 | Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. | Clin Cancer Res | 2023 |
| 37438216 | Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data. | Clin Lung Cancer | 2023 |
| 37272535 | Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC. | N Engl J Med | 2023 |
| 37236398 | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. | J Thorac Oncol | 2023 |
| 37196429 | Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. | J Clin Oncol | 2023 |
| 37196430 | Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. | J Clin Oncol | 2023 |
| 36720083 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. | J Clin Oncol | 2023 |
| 36849516 | Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. | Nat Commun | 2023 |
| 36811822 | Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. | Pharmacoecon Open | 2023 |
| 36841541 | Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). | J Thorac Oncol | 2023 |
| 36535627 | Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model. | J Thorac Oncol | 2023 |
| 36930839 | Using Recurrent Neural Networks to Extract High-Quality Information From Lung Cancer Screening Computerized Tomography Reports for Inter-Radiologist Audit and Feedback Quality Improvement. | JCO Clin Cancer Inform | 2023 |
| 36214668 | Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer. | Mol Cancer Res | 2023 |
| 34531139 | Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. | Clin Lung Cancer | 2022 |
| 35383171 | Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. | Nat Commun | 2022 |
| 35719866 | Automating Access to Real-World Evidence. | JTO Clin Res Rep | 2022 |
| 36439025 | Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts. | Cancer Inform | 2022 |
| 35907387 | PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC. | Lung Cancer | 2022 |
| 36333822 | Comparative analysis of the anthelmintic efficacy of European heather extracts on Teladorsagia circumcincta and Trichostrongylus colubriformis egg hatching and larval motility. | Parasit Vectors | 2022 |
| 35923926 | The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. | Ther Adv Med Oncol | 2022 |
| 36158638 | Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. | Ther Adv Med Oncol | 2022 |
| 35877212 | Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. | Curr Oncol | 2022 |
| 35012927 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. | Clin Cancer Res | 2022 |
| 35183992 | Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. | Lung Cancer | 2022 |
| 35278845 | Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. | Cancer Treat Res Commun | 2022 |
| 35121266 | Heather (Calluna vulgaris) supplementation does not reduce trapping ability of Duddingtonia flagrans in faeces of Haemonchus contortus infected lambs. | Vet Parasitol | 2022 |
| 35274718 | Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. | Oncologist | 2022 |
| 34688531 | Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. | Clin Lung Cancer | 2022 |
| 34740861 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. | J Thorac Oncol | 2022 |
| 34648945 | Lung Cancer Driven by BRAF<sup>G469V</sup> Mutation Is Targetable by EGFR Kinase Inhibitors. | J Thorac Oncol | 2022 |
| 32471890 | Clinical implementation of circulating tumour DNA testing for <i>EGFR</i> T790M for detection of treatment resistance in non-small cell lung cancer. | J Clin Pathol | 2021 |
| 33718025 | Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer patients. | Transl Lung Cancer Res | 2021 |
| 33582072 | Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. | Clin Lung Cancer | 2021 |
| 33582070 | Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. | Clin Lung Cancer | 2021 |
| 33775558 | Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). | Clin Lung Cancer | 2021 |
| 34917991 | Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy. | JTO Clin Res Rep | 2021 |
| 35112092 | Effects of Ethnicity on Outcomes of Patients With <i>EGFR</i> Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. | JTO Clin Res Rep | 2021 |
| 34723634 | A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. | Future Oncol | 2021 |
| 34716003 | EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. | J Thorac Oncol | 2021 |
| 34592536 | Stratification and management of patients ineligible for lung cancer screening. | Respir Med | 2021 |
| 33932863 | Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. | Lung Cancer | 2021 |
| 34145985 | The effect of prior cancer on non-small cell lung cancer trial eligibility. | Cancer Med | 2021 |